Novo Nordisk logo
Novo Nordisk
NONOF | OTC
Chart Builder DCF Calculator
$37.01
-$0.37 (-0.99%)
At close: Oct 2, 2026, 3:58 PM ET

Novo Nordisk Company Profile

Company profile explained

Company Profile

Novo Nordisk A/S operates as a prominent global pharmaceutical firm, dedicated to the discovery, development, production, and distribution of a wide array of medicinal products. Its extensive operations are primarily structured into two distinct divisions: Diabetes and Obesity Care, and Biopharmaceuticals. The Diabetes and Obesity Care segment offers comprehensive solutions, encompassing various insulin preparations, GLP-1 receptor agonists along with their delivery systems, oral antidiabetic medications, treatments for weight management, and therapies addressing other chronic health conditions. Meanwhile, the Biopharmaceuticals division is focused on specialized treatments for hemophilia, growth hormone disorders, and hormone replacement therapy. The company actively engages in strategic collaborations, notably including an agreement with Gilead Sciences, Inc. Furthermore, Novo Nordisk A/S is engaged in a research partnership with Lumen Bioscience, Inc., aiming to explore innovative methods for administering oral biologics for the management of cardiometabolic diseases. Established in 1923, the company's main corporate offices are located in Bagsvaerd, Denmark.

Key Executives

Name Position
Elin Jager SVP, Chief of Staff to CEO, Corporate Strategy & Sustainability and Member of Management Board
Maziar Mike Doustdar President, Chief Executive Officer & Member of the Management Board
Karsten Munk Knudsen Executive Vice President, Chief Financial Officer & Member of the Management Board
Emil Kongshøj Larsen EVP of International Operations & Member of Management Board
Hong Chow Executive Vice President of Product & Portfolio Strategy and Member of Management Board
Jamey Millar Executive Vice President of US Operations & Member of Management Board
John F. Kuckelman SVP, Group General Counsel, Global Legal, IP & Security and Member of Management Board
Martin Holst Lange EVP of R&D, Chief Scientific Officer and Member of the Management Board
Tania Sabroe EVP of People, Organisation and Corporate Affairs & Member of Management Board
Thilde Hummel Bogebjerg Executive VP of Enterprise IT & Quality and Member of Management Board
Novo Nordisk
Novo Nordisk logo
Country Denmark
IPO Date May 7, 2010
Industry Drug Manufacturers - General
Sector Healthcare
Employees 68,794
CEO Maziar Mike Doustdar

Contact Details

Novo Alle 1 Bagsvaerd, CR 2880 Denmark

Stock Details

Ticker Symbol NONOF
Exchange OTC
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000353278
CUSIP Number n/a
ISIN Number DK0062498333
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.